drugset / Trial / NCT03664011

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

NCT03664011

Phase 1 Completed 6 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objectives of the study are as follows: * To assess the mass balance recovery of (C-14) BI 730357-radioactivity (also expressed as 14C-BI 730357-EQ) in urine and faeces after a single oral dose of 50 mg BI 730357 base (BS) (C-14) in healthy male subjects * To provide plasma, urine, and faecal samples for metabolite profiling and structural identification

Timeline

Start
2018-09-10
Primary completion
2018-11-13
Completion
2018-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 730357 Unknown 50 mg Oral

Indications

No indication recorded.